180 Life Sciences Files A Provisional Patent For CBD-Based Appetite Suppressant
180 Life Sciences Corp. (NASDAQ: ATNF) filed a provisional patent describing the novel combination of CBD, or an analog thereof, with glucagon related peptide-1 (GLP-1) agonists to address the problem of obesity and wei
